MAP2K7 and colorectal carcinoma: Importantly, the mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor selumetinib and the ferroptosis inducer sulfasalazine effectively suppress ESSENCE-high CRC in a patient-derived xenograft (PDX) model.